Get the Stockscreener App
2.96
2.42%
0.07
Onkure Therapeutics Inc stock is traded at $2.96, with a volume of 8,037.
It is up +2.42% in the last 24 hours and up +23.85% over the past month.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
See More
Previous Close:
$2.89
Open:
$2.89
24h Volume:
8,037
Relative Volume:
0.09
Market Cap:
$37.50M
Revenue:
-
Net Income/Loss:
$-70.20M
P/E Ratio:
-0.066
EPS:
-44.82
Net Cash Flow:
$-50.66M
1W Performance:
-2.63%
1M Performance:
+23.85%
6M Performance:
-1.33%
1Y Performance:
-84.21%
1-Day Range:
$2.85
$3.0373
1-Week Range:
$2.70
$3.27
52-Week Range:
$1.70
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Name
Onkure Therapeutics Inc
Sector
Industry
Phone
(720) 307-2892
Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.92 | 39.10M | 0 | -70.20M | -50.66M | -44.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.08 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
479.20 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.53 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
814.57 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
315.06 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Initiated | Evercore ISI | Outperform |
| Dec-05-24 | Initiated | Leerink Partners | Outperform |
| Oct-10-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-15-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-14-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-23 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Dec-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-14-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-15-23 | Initiated | William Blair | Outperform |
| Aug-28-23 | Initiated | H.C. Wainwright | Buy |
| Jul-03-23 | Initiated | BofA Securities | Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jan-27-22 | Initiated | Robert W. Baird | Outperform |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-22-21 | Initiated | Ladenburg Thalmann | Buy |
| May-04-21 | Initiated | Jefferies | Buy |
| May-04-21 | Initiated | Piper Sandler | Overweight |
| May-04-21 | Initiated | SVB Leerink | Outperform |
View All
Onkure Therapeutics Inc Stock (OKUR) Latest News
Can you recover from losses in OnKure Therapeutics Inc.Market Performance Summary & Weekly High Conviction Ideas - newser.com
Will OnKure Therapeutics Inc. stock continue upward momentumCEO Change & Momentum Based Trading Signals - newser.com
How institutional ownership impacts OnKure Therapeutics Inc. stockWeekly Stock Recap & AI Powered Trade Plan Recommendations - newser.com
What MACD signals say about OnKure Therapeutics Inc.Inflation Watch & Safe Entry Point Identification - newser.com
Can trapped investors hope for a rebound in OnKure Therapeutics Inc.July 2025 Momentum & Safe Investment Capital Preservation Plans - newser.com
OnKure Therapeutics Inc. stock volume spike explainedEarnings Beat & High Accuracy Buy Signal Tips - newser.com
Relative strength of OnKure Therapeutics Inc. in sector analysisMarket Weekly Review & Step-by-Step Trade Execution Guides - newser.com
How OnKure Therapeutics Inc. stock trades before earningsTrade Risk Assessment & Fast Moving Stock Trade Plans - newser.com
Using Python tools to backtest OnKure Therapeutics Inc. strategiesDay Trade & AI Enhanced Execution Alerts - newser.com
What data driven models say about OnKure Therapeutics Inc.’s future2025 Market Outlook & Daily Stock Trend Watchlist - newser.com
Applying Wyckoff theory to OnKure Therapeutics Inc. stockEarnings Summary Report & Daily Momentum Trading Reports - newser.com
What analysts say about OnKure Therapeutics Inc stockTrading Volume Surges & High Return Wealth Plans - earlytimes.in
What drives OnKure Therapeutics Inc stock priceGrowth vs. Value Investing & You’ve Never Seen Stock Picks Like These - earlytimes.in
Advanced analytics toolkit walkthrough for OnKure Therapeutics Inc.Portfolio Growth Summary & Stepwise Trade Execution Plans - newser.com
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Raises Target Price to $21 - 富途牛牛
Onkure Therapeutics Inc Stock (OKUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Onkure Therapeutics Inc Stock (OKUR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Sep 22 '25 |
Sale |
2.62 |
303 |
795 |
12,603 |
| Saccomano Nicholas A | President and CEO |
Jun 23 '25 |
Sale |
2.38 |
88 |
210 |
3,594 |
| Leverone Jason A. | Chief Financial Officer |
Jun 23 '25 |
Sale |
2.38 |
303 |
722 |
12,906 |
| Cormorant Asset Management, LP | Former 10% Owner |
May 15 '25 |
Sale |
1.85 |
1,813,439 |
3,363,023 |
0 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
1,129,730 |
2,090,000 |
1,129,730 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
270,270 |
500,000 |
1,709,944 |
| Cormorant Asset Management, LP | 10% Owner |
May 12 '25 |
Sale |
1.99 |
24,300 |
48,236 |
1,813,439 |
| Saccomano Nicholas A | President and CEO |
Apr 07 '25 |
Sale |
2.67 |
516 |
1,378 |
3,682 |
| Saccomano Nicholas A | President and CEO |
Apr 04 '25 |
Sale |
3.33 |
358 |
1,191 |
4,198 |
| Leverone Jason A. | Chief Financial Officer |
Apr 07 '25 |
Sale |
2.67 |
1,844 |
4,925 |
13,209 |
1.26%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):